Zinc finger-inspired peptide-metal-phenolic nanointerface enhances bone-implant integration under bacterial infection microenvironment through immune modulation and osteogenesis promotion.

Xu L, Fang J, Pan J, Qi H, Yin Y, He Y, Gan X, Li Y, Li Y, Guo J

Bioactive materials23 Aug 2024Cited by 26 (Europe PMC)

PMID39257672PMCIDPMC11384338DOI10.1016/j.bioactmat.2024.08.009PepBankPUB-39257672

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study11

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone11

In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Abaloparatide (Tymlos).

01AnimalNot a test of Abaloparatide (Tymlos) aloneAnimal study (in vivo)Efficacy outcome
In infected rat bone defects, ABL@ZnTA significantly reduced inflammatory fibrous tissue encapsulation.
In plain wordsIn rats with infected bone defects, the abaloparatide-containing nanocoating reduced inflammatory tissue around implants.
Peptide
Abaloparatide (Tymlos)
Outcome
DecreaseInflammatory fibrous encapsulation
Study
ratn: not reported in source
S. aureus-infected bone defect
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Furthermore, the ABL@ZnTA significantly reduces inflammatory fibrous tissue encapsulation and enhances the long-term stability of the implants, indicated by enhanced binding strength (6 times) and functional connectivity (1.5-3 times) in the rat bone defect model infected by S. aureus.
1 context sentence(design, population, supporting numbers)
Summary · context
Abaloparatide (ABL), a second-generation anabolic drug for treating osteoporosis, can be integrated into the design of a zinc-phenolic network constructed on the implant surface (ABL@ZnTA).
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Report a problemFND-3925767209
02AnimalNot a test of Abaloparatide (Tymlos) aloneAnimal study (in vivo)Efficacy outcome
In infected rat bone defects, ABL@ZnTA enhanced implant binding strength 6 times.
In plain wordsIn rats with infected bone defects, the abaloparatide-containing nanocoating enhanced implant binding strength 6 times.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseImplant binding strength
Study
ratn: not reported in source
S. aureus-infected bone defect
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Furthermore, the ABL@ZnTA significantly reduces inflammatory fibrous tissue encapsulation and enhances the long-term stability of the implants, indicated by enhanced binding strength (6 times) and functional connectivity (1.5-3 times) in the rat bone defect model infected by S. aureus.
1 context sentence(design, population, supporting numbers)
Summary · context
Abaloparatide (ABL), a second-generation anabolic drug for treating osteoporosis, can be integrated into the design of a zinc-phenolic network constructed on the implant surface (ABL@ZnTA).
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Report a problemFND-3925767210
03AnimalNot a test of Abaloparatide (Tymlos) aloneAnimal study (in vivo)Efficacy outcome
In infected rat bone defects, ABL@ZnTA enhanced functional connectivity 1.5-3 times.
In plain wordsIn rats with infected bone defects, the abaloparatide-containing nanocoating enhanced functional connectivity 1.5-3 times.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseImplant functional connectivity
Study
ratn: not reported in source
S. aureus-infected bone defect
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Furthermore, the ABL@ZnTA significantly reduces inflammatory fibrous tissue encapsulation and enhances the long-term stability of the implants, indicated by enhanced binding strength (6 times) and functional connectivity (1.5-3 times) in the rat bone defect model infected by S. aureus.
1 context sentence(design, population, supporting numbers)
Summary · context
Abaloparatide (ABL), a second-generation anabolic drug for treating osteoporosis, can be integrated into the design of a zinc-phenolic network constructed on the implant surface (ABL@ZnTA).
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Report a problemFND-3925767211
04LabNot a test of Abaloparatide (Tymlos) aloneIn vitro (cell-free)Other
In the nanocoating, zinc ions stabilized abaloparatide configuration through multiple molecular interactions.
In plain wordsIn lab tests, zinc ions stabilized abaloparatide within the nanocoating.
Peptide
Abaloparatide (Tymlos)
Outcome
Not applicableABL configuration stabilization
Study
n: not reported in source
Outcome group
Pharmacokinetics · Pharmacology
Source sentences
Summary
Importantly, the phenolic-coordinated Zn²⁺ ions in ABL@ZnTA can act as zinc finger motif to co-stabilize the configuration of ABL through multiple molecular interactions
1 context sentence(design, population, supporting numbers)
Summary · context
Abaloparatide (ABL), a second-generation anabolic drug for treating osteoporosis, can be integrated into the design of a zinc-phenolic network constructed on the implant surface (ABL@ZnTA).
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Report a problemFND-3925767201
05LabNot a test of Abaloparatide (Tymlos) aloneIn vitro (cell-free)Other
The abaloparatide-containing ABL@ZnTA nanocoating enabled high bioactivity without a numerical estimate.
In plain wordsIn lab tests, the abaloparatide-containing nanocoating showed high bioactivity without a numerical estimate.
Peptide
Abaloparatide (Tymlos)
Outcome
Direction not reportedBioactivity
Study
n: not reported in source
Outcome group
Pharmacokinetics · Pharmacology
Source sentences
Summary
enabling high bioactivity, high loading capacity (1.36 times), and long-term release (>7 days) of ABL.
1 context sentence(design, population, supporting numbers)
Summary · context
Abaloparatide (ABL), a second-generation anabolic drug for treating osteoporosis, can be integrated into the design of a zinc-phenolic network constructed on the implant surface (ABL@ZnTA).
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Report a problemFND-3925767202
06LabNot a test of Abaloparatide (Tymlos) aloneIn vitro (cell-free)Other
The abaloparatide-containing ABL@ZnTA nanocoating enabled a loading capacity of 1.36 times, with an unspecified reference.
In plain wordsIn lab tests, the nanocoating enabled 1.36 times loading capacity, with no specified reference.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseLoading capacity
Study
n: not reported in source
Outcome group
Pharmacokinetics · Pharmacology
Source sentences
Summary
enabling high bioactivity, high loading capacity (1.36 times), and long-term release (>7 days) of ABL.
1 context sentence(design, population, supporting numbers)
Summary · context
Abaloparatide (ABL), a second-generation anabolic drug for treating osteoporosis, can be integrated into the design of a zinc-phenolic network constructed on the implant surface (ABL@ZnTA).
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Report a problemFND-3925767203
07LabNot a test of Abaloparatide (Tymlos) aloneIn vitro (cell-free)Other
The abaloparatide-containing ABL@ZnTA nanocoating enabled abaloparatide release for more than 7 days.
In plain wordsIn lab tests, the nanocoating released abaloparatide for more than 7 days.
Peptide
Abaloparatide (Tymlos)
Outcome
Not applicableABL release duration
Study
n: not reported in source
Outcome group
Pharmacokinetics · Pharmacology
Source sentences
Summary
enabling high bioactivity, high loading capacity (1.36 times), and long-term release (>7 days) of ABL.
1 context sentence(design, population, supporting numbers)
Summary · context
Abaloparatide (ABL), a second-generation anabolic drug for treating osteoporosis, can be integrated into the design of a zinc-phenolic network constructed on the implant surface (ABL@ZnTA).
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Report a problemFND-3925767204
08LabNot a test of Abaloparatide (Tymlos) aloneOther designMechanism
ABL@ZnTA shifted macrophage polarization from the pro-inflammatory M1 phenotype toward the anti-inflammatory M2 phenotype.
In plain wordsIn lab tests, the abaloparatide-containing nanocoating shifted macrophages from an inflammatory phenotype toward an anti-inflammatory phenotype.
Peptide
Abaloparatide (Tymlos)
Outcome
MixedMacrophage polarization
Study
n: not reported in source
Outcome group
Immune response · Immune and inflammation
Source sentences
Summary
Our results showed that ABL@ZnTA can modulate macrophage polarization from the pro-inflammatory M1 towards the anti-inflammatory M2 phenotype, promoting immune osteogenesis with increased OCN, ALP, and SOD 1 expression.
1 context sentence(design, population, supporting numbers)
Summary · context
Abaloparatide (ABL), a second-generation anabolic drug for treating osteoporosis, can be integrated into the design of a zinc-phenolic network constructed on the implant surface (ABL@ZnTA).
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Report a problemFND-3925767205
09LabNot a test of Abaloparatide (Tymlos) aloneOther designMechanism
The abaloparatide-containing ABL@ZnTA nanocoating increased OCN expression during immune osteogenesis.
In plain wordsIn lab tests, the abaloparatide-containing nanocoating increased OCN expression.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseOCN expression
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Our results showed that ABL@ZnTA can modulate macrophage polarization from the pro-inflammatory M1 towards the anti-inflammatory M2 phenotype, promoting immune osteogenesis with increased OCN, ALP, and SOD 1 expression.
1 context sentence(design, population, supporting numbers)
Summary · context
Abaloparatide (ABL), a second-generation anabolic drug for treating osteoporosis, can be integrated into the design of a zinc-phenolic network constructed on the implant surface (ABL@ZnTA).
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Report a problemFND-3925767206
10LabNot a test of Abaloparatide (Tymlos) aloneOther designMechanism
The abaloparatide-containing ABL@ZnTA nanocoating increased ALP expression during immune osteogenesis.
In plain wordsIn lab tests, the abaloparatide-containing nanocoating increased ALP expression.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseALP expression
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Our results showed that ABL@ZnTA can modulate macrophage polarization from the pro-inflammatory M1 towards the anti-inflammatory M2 phenotype, promoting immune osteogenesis with increased OCN, ALP, and SOD 1 expression.
1 context sentence(design, population, supporting numbers)
Summary · context
Abaloparatide (ABL), a second-generation anabolic drug for treating osteoporosis, can be integrated into the design of a zinc-phenolic network constructed on the implant surface (ABL@ZnTA).
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Report a problemFND-3925767207
11LabNot a test of Abaloparatide (Tymlos) aloneOther designMechanism
The abaloparatide-containing ABL@ZnTA nanocoating increased SOD 1 expression during immune osteogenesis.
In plain wordsIn lab tests, the abaloparatide-containing nanocoating increased SOD 1 expression.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseSOD 1 expression
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Our results showed that ABL@ZnTA can modulate macrophage polarization from the pro-inflammatory M1 towards the anti-inflammatory M2 phenotype, promoting immune osteogenesis with increased OCN, ALP, and SOD 1 expression.
1 context sentence(design, population, supporting numbers)
Summary · context
Abaloparatide (ABL), a second-generation anabolic drug for treating osteoporosis, can be integrated into the design of a zinc-phenolic network constructed on the implant surface (ABL@ZnTA).
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Report a problemFND-3925767208

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.